Nectin-4 is an important target that has been shown to be available as a treatment for locally advanced and advanced bladder cancer. Based on this, Padcev (enfortumab-vedotin-ejfv), the first ADC drug (antibody-coupled drug) for uroepithelial carcinoma, has also received accelerated FDA approval for the treatment of locally advanced or advanced bladder cancer in patients who have previously received immune checkpoint inhibitors (PD-L1, PD-1) and platinum-containing chemotherapy before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). Adult patients with advanced or late-stage uroepithelial carcinoma (a common type of bladder cancer).
"Cancer"
-
-
Apparatus
New CAR-T Therapy CB-010, Granted Two FDA Designations And Three Patients Are Cancer-Free For Six Months!
According to an announcement from Caribou Biosciences, the FDA has granted advanced therapy designation in regenerative medicine for the cutting-edge CAR-T therapy CB-010 for the treatment of relapsed or refractory large B-cell lymphoma and fast track designation for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
-
Medical
Significant Improvement In Survival For Pancreatic Cancer Patients! A first-Line NALIRIFOX Regimen To Look Forward To!
As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.
-
Christie Hospital, based in Manchester, is one of the top three cancer centres in Europe, with 2,500 staff, 300 volunteers and 30,000 members, treating over 44,000 patients each year
-
Apparatus
Over 30% Of Tumours In Advanced Lung Cancer Patients In Remission With Frontier Drug Teliso-V In Combination With Troche!
Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).
-
With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.
-
Apparatus
Check breast cancer like drinking and driving: breath detector capable of diagnosing various diseases
When it comes to the breath detector, everyone will think of the thing used by the traffic police to check drinking and driving. For those who drink and drive, they will lose their temper when they see the breath detector. In fact, the gas exhaled by the human body has many characteristics. It can not only detect alcohol, but also reflect the health of the human body and detect some diseases. This breath detector introduced in this article can detect breast cancer, diabetes, lung cancer, Parkinson's disease, asthma, schizophrenia, kidney and liver failure and other diseases.
-
Medical
Neoadjuvant Chemotherapy Reduces Colon Cancer Recurrence Rate By 28%, With Fewer Post-Operative Complications, Study Shows
Preoperative oxaliplatin-fluoropyrimidine chemotherapy given to colon cancer patients did not increase the risk of perioperative complications in colon cancer patients and did reduce postoperative recurrence rates, according to the results of the international phase 3/4 FOxTROT trial.
-
Apparatus
New Targeted Drug For Leukaemia Approved, 35% Of Patients' Cancer Cells Disappear Completely!
The US FDA has approved a new leukaemia drug, Olutasidenib, which has been shown to be effective and has a controlled safety profile, resulting in the complete disappearance of cancer cells in 35% of patients enrolled, with efficacy lasting up to 25.9 months.
-
Medical
New Research Shows Promise For Bone Marrow Transplant Recipient Patients To Reduce Treatment Side Effects!
Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.